证券代码：002162 证券简称：悦心健康 公告编号：2025-036 上海悦心健康集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 上海悦心健康集团股份有限公司（以下简称"公司"）分别于2025年2月26日、 《关于公司回购股份方案的议案》，同意公司使用自有资金或自筹资金以集中竞价 交易的方式回购公司部分已发行的人民币普通股（A股）股票，回购股份将全部用于 注销并减少公司注册资本。本次回购总金额不低于人民币600万元（含）且不超过人 民币1,000万元（含），回购价格为不超过人民币5元/股（含），具体回购数量以回 购期限届满时实际回购的股份数量为准。回购股份的期限自股东大会审议通过回购 股份方案之日起不超过12个月。具体内容详见公司于2025年2月28日、2025年4月19 日披露在巨潮资讯网（www.cninfo.com.cn）上的《关于回购公司股份方案的公告》 （公告编号：2025-017）、《回购报告书》（公告编号：2025-033）。 已实施完毕。根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管 指引第9号——回购股 ...

Group 1 - The core concept of "Chuan Xiaopu" is to provide a low-cost entrepreneurial model in the health sector, allowing individuals to start their own business with an investment of over 2000 yuan, while receiving health products and professional guidance [2] - The model addresses the employment challenges faced by university graduates in a competitive job market, offering a new avenue for economic independence and self-worth [2][3] - "Chuan Xiaopu" aligns with the growing consumer demand for health products and services, capitalizing on the increasing health awareness among the public [3] Group 2 - The entrepreneurial model not only helps individuals achieve self-value but also contributes to alleviating employment pressure by providing valuable labor to society [3] - The future expansion of "Chuan Xiaopu" is expected to attract more entrepreneurs, further addressing employment issues and invigorating the health industry [4] - The brand aims to transform from a health product provider to a lifestyle leader, promoting a comprehensive health management system for families [4]

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0090 | -0.0141 | 36.17 | -0.0083 | | 每股净资产（元） | 0.89 | 1.06 | -16.04 | 1.08 | | 每股公积金(元) | 0.2 | 0.22 | -9.09 | 0.21 | | 每股未分配利润(元) | -0.47 | -0.31 | -51.61 | -0.36 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.96 | 2.21 | -11.31 | 2.21 | | 净利润(亿元) | -0.08 | -0.13 | 38.46 | -0.08 | | 净资产收益率(%) | -1.01 | -1.32 | 23.48 | -0.77 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 52789.84万股，累计 ...